News
Remix Therapeutics, a biotechnology company in the clinical stage, is pioneering the development of small molecule therapies targeting RNA processing to combat the root causes of diseases. Today, they announced a significant step forward with
Read more...Tenax Therapeutics, Inc. has announced that the United States Patent and Trademark Office has granted the company a patent covering the use of several forms of levosimendan,
Read more...Wave Life Sciences Ltd. has announced the approval of its first clinical trial application for the RestorAATion-2 trial of WVE-006, a novel RNA editing oligonucleotide designed to treat alpha-1 antitrypsin deficiency
Read more...30 April 2024
X4 Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved XOLREMDI™ capsules for patients aged 12 and above diagnosed with WHIM syndrome
Read more...29 April 2024
Amgen recently announced its plans to submit a Marketing Authorization Application to the European Medicines Agency for teprotumumab, a fully human monoclonal antibody designed to treat moderate to severe Thyroid Eye Disease
Read more...26 April 2024
Freedom Biosciences, Inc. has received notification from the U.S. Food and Drug Administration (FDA) greenlighting the initiation of its FREE001-TRD-201 study, a Phase 2a clinical trial for FREE001
Read more...25 April 2024
Deverra Therapeutics, Inc., a biotechnology company specializing in developing advanced cell therapies for cancer and other serious diseases, has announced that the U.S. Food and Drug Administration
Read more...25 April 2024
Ascendis Pharma A/S has announced that the Medicines & Healthcare Products Regulatory Agency in the United Kingdom has given the green light to YORVIPATH®. This marks a significant step forward as it's now authorized for treating adults
Read more...Tiziana Life Sciences, Ltd., a biotech company focused on developing innovative immunomodulation therapies through unique drug delivery methods, has received approval from the U.S. Food and Drug Administration
Read more...23 April 2024
Acadia Pharmaceuticals Inc. has announced that Health Canada has accepted its New Drug Submission for trofinetide, a potential treatment for Rett syndrome, a rare neurodevelopmental disorder.
Read more...